

Supplemental Combined Declaration and Power of Attorney for Patent Application

Docket Number: 18528.032 / 231 / 181 US

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled Use of Exendins for the Reduction of Food Intake, the specification of which is attached hereto unless the following box is checked:

- ☒ was filed on January 7, 1998;
as United States Application Number 09/003,869; and
was amended on April 22, 2004 (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application, which designated at least one country other than the United States listed below, and have also identified below any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Claimed

(Application No.)

(Country)

(Day/Month/Year Filed)

☐ Yes ☐ No

(Application No.)

(Country)

(Day/Month/Year Filed)

☐ Yes ☐ No

I hereby claim the benefit under 35 U.S.C. § 119(c) of any United States provisional application(s) listed below.

60/034,905
(Application No.)1/7/1997
(Filing Date)60/055,404
(Application No.)8/8/1997
(Filing Date)60/066,029
(Application No.)11/14/1997
(Filing Date)60/066,442
(Application No.)11/14/1997
(Filing Date)

- Page 1 of 3 -

BEST AVAILABLE COPY

Application No. 09/003,869
Docket No. 18528.032 / 231/181 US

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or under § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56 that became available between the filing date of the prior application and the national or PCT international filing date of this application.

_____ (Application No.)	_____ (Filing Date)	_____ (Status - patented, pending, abandoned)
----------------------------	------------------------	--

_____ (Application No.)	_____ (Filing Date)	_____ (Status - patented, pending, abandoned)
----------------------------	------------------------	--

_____ (Application No.)	_____ (Filing Date)	_____ (Status - patented, pending, abandoned)
----------------------------	------------------------	--

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

practitioners at Arnold & Porter LLP and Amylin Pharmaceuticals, Inc.,
associated with Customer No. **44638**;



Send Correspondence to:

David R. Marsh
ARNOLD & PORTER LLP
Attn: IP Docketing Dept.
555 12th Street, N.W.
Washington, D.C. 20004-1206
Facsimile: (202) 942-5999

Direct Telephone Calls to: (202) 942-5000

Application No. 09/003,869
Docket No. 18528.032/ 231/181 US

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor:	Andrew A. YOUNG	
Inventor's signature		Date 14 JULY 2004
Residence	La Jolla, California	
Citizenship	New Zealand	
Post Office Address	2035 Caminito El Canario	
	La Jolla, California 92037	
Full name of second inventor:	Sunil Praful BHAVSAR	
Inventor's signature		Date 14 July 2004
Residence	San Diego, California	
Citizenship	United States of America	
Post Office Address	8809 La Cartera Street	
	San Diego, California 92129	

BEST AVAILABLE COPY

STATEMENT UNDER 37 CFR 3.73(b)

Applicant: Beeley et al.

Application No./Patent No.: 09/003,869

Filed/Issue Date: January 7, 1998

Entitled: Use of Exendins for the Reduction of Food Intake

Amylin Pharmaceuticals, Inc., a corporation, states that it is:

1. ☒ the assignee of the entire right, title and interest or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership is

In the patent application/patent identified above by virtue of:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 9381, Frame 0222, or for which a copy thereof is attached

AND

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Andrew A. Young To: Amylin Pharmaceuticals, Inc.
The document was recorded in the United States Patent Office at
Reel ____, Frame ____, or for which a copy thereof is attached.


- ☒ Copies of the assignments or other documents in the chain of title are attached
[NOTE: A separate copy (i.e., the original document or a true copy of the original document) must be submitted to the Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Date: 7/14/04

Telephone: (858) 642-7066

AMYLIN PHARMACEUTICALS, INC.



Lloyd Royland
Vice President, General Counsel and
Secretary

BEST AVAILABLE COPY